CN113717138A - Nitrogen mustard chromone derivatives and application thereof - Google Patents
Nitrogen mustard chromone derivatives and application thereof Download PDFInfo
- Publication number
- CN113717138A CN113717138A CN202111227792.2A CN202111227792A CN113717138A CN 113717138 A CN113717138 A CN 113717138A CN 202111227792 A CN202111227792 A CN 202111227792A CN 113717138 A CN113717138 A CN 113717138A
- Authority
- CN
- China
- Prior art keywords
- nitrogen mustard
- reaction
- compound
- pharmaceutically acceptable
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a nitrogen mustard chromone derivative and application thereof, belonging to the fields of natural medicines and medicinal chemistry. In particular to a preparation method of a series of nitrogen mustard chromone derivatives with anti-tumor activity and new application in anti-tumor drugs. The nitrogen mustard chromone derivative and the pharmaceutically acceptable salt thereof are shown in a general formula I. Wherein, R, R1And X is as described in the claims and specification.
Description
Technical Field
The invention belongs to the field of natural medicines and medicinal chemistry, relates to nitrogen mustard chromone derivatives and application, and particularly relates to a preparation method of a series of nitrogen mustard chromone derivatives with anti-tumor activity and application of the nitrogen mustard chromone derivatives in the aspect of anti-tumor.
Background
Chromone is an oxygen-containing heterocyclic compound with a benzo-gamma-pyrone framework, is widely distributed in the natural world and has various remarkable biological activities. Chromone and derivatives thereof show good antiproliferative activity on breast cancer, liver cancer, lung cancer, leukemia, colon cancer and the like, play a role through multiple mechanisms and have great potential in cancer treatment. However, the further development and application of the compound are limited due to the defects of poor bioavailability, insufficient activity intensity and the like. Therefore, modifications and alterations to the structure of chromones are needed to obtain candidate drugs with better activity.
Nitrogen mustards, also known as DNA alkylating agents, belong to the cytotoxic class of drugs. The medicine is widely used clinically, but the toxic and side effects of the medicine are large, the specificity of the effect on cells is lacked, and the treatment effect is not ideal along with the occurrence of tumor drug resistance in recent years. Therefore, the chemical modification of the nitrogen mustard drugs to improve the curative effect thereof has important value.
Disclosure of Invention
The invention aims to solve the technical problem of searching nitrogen mustard chromone derivatives with good antitumor activity and pharmaceutically acceptable salts thereof and further providing a pharmaceutical composition.
In order to solve the technical problems, the invention provides the following technical scheme:
a nitrogen mustard chromone derivative and a pharmaceutically acceptable salt thereof have the following structural general formula I:
wherein R is an alkyl group having 1 to 8 carbon atoms or an alkoxy group having 1 to 8 carbon atoms; r1Is H, or an alkyl or alkoxy group containing 1 to 10 carbon atoms; the heteroatom X is N, O, S or Se.
Preferably, R isAn alkyl group having 1 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon atoms; r1Is H, or an alkyl or alkoxy group containing 1 to 8 carbon atoms; the heteroatom X is N, O or S.
More preferably, R is an alkyl group containing 1 to 4 carbon atoms or an alkoxy group containing 1 to 4 carbon atoms; r1Is H, or an alkyl or alkoxy group containing 1 to 6 carbon atoms; the heteroatom X is N or O.
Further, the following derivatives and pharmaceutically acceptable salts thereof are preferred in the invention, and the structural formulas are shown as a-h:
the derivative of the invention can be prepared by the following method:
(1) reacting the compound 1a-b with phosphorus oxychloride in N, N-dimethylformamide at room temperature to obtain an intermediate 2 a-b; then the intermediate 2a-b is dissolved in isopropanol and alkaline Al is added2O3Carrying out reflux reaction to obtain a compound 3 a-b; dissolving the compounds 3a-b in dichloromethane, dropwise adding phosphorus tribromide under an ice bath condition, transferring to room temperature for reaction, dissolving the treated solid in N, N-dimethylformamide, adding ammonia water, and reacting at room temperature to obtain compounds 4 a-b;
(2) reaction of melphalan 5 with acetic anhydride in formic acid to give compound 6 a; or reacting melphalan 5 with di-tert-butyl carbonate in dioxane solvent in the presence of triethylamine to obtain a compound 6 b;
(3) dissolving the compound 3a-b or 4a-b in anhydrous dichloromethane, sequentially adding EDCI, DMAP or HOBt, and reacting with the compound 6a-b at room temperature to obtain target compounds 7a-d and 8 a-d.
A pharmaceutical composition, which comprises a therapeutically effective amount of the nitrogen mustard chromone derivative shown in the general formula I and pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
The nitrogen mustard chromone derivative shown in the general formula I and the pharmaceutically acceptable salt thereof are applied to preparing the medicines for treating tumor diseases.
Furthermore, the tumor is breast cancer tumor or liver cancer tumor.
The application of the pharmaceutical composition in preparing medicines for treating tumor diseases.
Furthermore, the tumor is breast cancer tumor or liver cancer tumor.
The invention takes chromone as a lead compound, designs and synthesizes nitrogen mustard chromone derivatives, and tests the biological activity of the synthesized derivatives in the aspect of anti-tumor.
Pharmacological tests prove that the nitrogen mustard chromone derivative has good anti-tumor cell proliferation effect and can be used for further preparing anti-tumor drugs.
Detailed Description
The following non-limiting examples will allow one of ordinary skill in the art to more fully understand the present invention, but are not intended to limit the invention in any way.
The synthesis route of the derivatives of the embodiment of the invention is as follows:
example 1
(1) 500mg of compound 1a (3.33mmol) was dissolved in 10mL of DMF, and 630. mu.L of phosphorus oxychloride (6.72mmol) was added dropwise and reacted at room temperature for 12 hours. TLC monitoring, reaction is basically complete, 15mL water is added, crystallization is separated out, suction filtration and drying are carried out, and the product is obtainedIntermediate 2a 402.4 mg. 50mg of intermediate 2a (0.27mmol) are dissolved in 10mL of isopropanol and 1g of basic Al are added2O3(9.80mmol) and then the reaction was refluxed at 75 ℃ for 5 h. TLC monitoring, reaction completed, suction filtration, filtrate concentration to get crude product, silica gel column chromatography (DCM: MeOH) separation to get compound 3a (R ═ CH)3)。
(2) 500mg of melphalan 5(1.64mmol) are dissolved in 15mL of formic acid, 2mL of acetic anhydride are then added and the reaction is carried out in an oil bath at 50 ℃ for 5 h. After the reaction is completed, adding a proper amount of water, extracting with dichloromethane for 3 times, washing with saturated saline for 1 time, drying over anhydrous sodium sulfate, filtering, and concentrating to obtain a compound 6a (R)1＝-H)。
(3) 50mg of compound 3a (0.26mmol) was dissolved in 5mL of anhydrous dichloromethane, and 151.6mg of EDCI (0.80mmol), 16.1mg of DMAP (0.13mmol), 69.7mg of compound 6a (0.21mmol) were added and reacted at room temperature for 12 h. After the reaction was completed, the reaction solution was poured into water, extracted with dichloromethane 3 times, washed with saturated brine 1 time, and anhydrous Na2SO4Drying and concentrating to obtain a crude product. Silica gel column chromatography (DCM: MeOH) afforded title compound 7 a. Yellow oil, yield 35.4%.1H NMR(CDCl3,400MHz),δ:8.18(1H,s,-CHO),8.04(1H,d,J＝1.8Hz,5-H),7.95(1H,s,-2-H),7.52(1H,dd,J＝8.6,2.0Hz,7-H),7.39(1H,d,J＝8.6Hz,8-H),6.98(2H,d,J＝8.8Hz,Ar-H),6.50(2H,d,J＝8.8Hz,Ar-H),6.07(1H,d,J＝7.7Hz,-NH),5.16,5.06(each 1H,d,J＝12.4Hz,-CH2),4.92(1H,m,-CH),3.62(4H,m,-CH2),3.56(4H,m,-CH2),3.08,3.03(each 1H,dd,J＝14.0,5.5Hz,-CH2),2.47(3H,s,-CH3)；13C NMR(CDCl3,100MHz),δ:176.54,171.27,160.44,156.03,154.73,145.12,135.77,135.42,130.71(2),125.25,124.22,123.67,118.63,118.00,112.05(2),59.37,53.45(2),52.03,40.29(2),36.66,20.98；HRMS(ESI)m/z calcd for C25H25Cl2N2O5[M-H]-503.1141,found 503.1129。
Example 2
Example 1 the procedure for the synthesis of 3a in step (1) was replaced by: 553mg of Compound 1b (3.33mmol) were dissolved in 10mL of DMF, and then 630. mu.L of phosphorus oxychloride (6.72mmol) was added dropwise and reacted at room temperature for 12 hours. TLC monitoring, reaction is almost complete, 15mL water is added, crystal is separated out, suction filtration and drying are carried out, and the intermediate 2b 410mg is obtained. 55mg of intermediate 2b (0.27mmol) were dissolved in 10mL of isopropanol and 1g of basic Al was added2O3(9.80mmol) and then the reaction was refluxed at 75 ℃ for 5 h. TLC monitoring, reaction completed, suction filtration, filtrate concentration to get crude product, silica gel column chromatography (DCM: MeOH) separation to get compound 3b (R ═ OCH)3)。
The remaining steps were performed according to the synthetic method of example 1 to obtain compound 7b as a yellow oil in 39.2% yield.1H NMR(CDCl3,400MHz),δ:8.18(1H,s,-CHO),7.96(1H,s,2-H),7.60(1H,d,J＝3.1Hz,5-H),7.43(1H,d,J＝9.1Hz,8-H),7.30(1H,dd,J＝9.1,3.1Hz,7-H),6.98(2H,d,J＝8.7Hz,Ar-H),6.50(2H,d,J＝8.7Hz,Ar-H),6.06(1H,d,J＝7.6Hz,-NH),5.16,5.08(each1H,d,J＝12.4Hz,-CH2),4.92(1H,m,-CH),3.91(3H,s,-OCH3),3.63(4H,m,-CH2),3.57(4H,m,-CH2),3.09,3.03(each 1H,m,-CH2)；13C NMR(CDCl3,100MHz),δ:176.31,171.27,160.45,157.30,155.81,151.28,145.20,130.69(2),124.62,124.21,124.14,119.67,118.02,112.00(2),105.01,59.39,56.00,53.43(2),52.04,40.33(2),36.66；HRMS(ESI)m/z calcd for C25H25Cl2N2O6[M-H]-519.1090,found 519.1094。
Example 3
Example 1 the procedure for the synthesis of 3a in step (1) was replaced by: 500mg of compound 1a (3.33mmol) was dissolved in 10mL of DMF, and 630. mu.L of phosphorus oxychloride (6.72mmol) was added dropwise and reacted at room temperature for 12 hours. TLC monitoring, reaction is basically complete, 15mL water is added, crystallization is separated out, suction filtration and drying are carried out, and the intermediate 2a is obtained402.4 mg. 50mg of intermediate 2a (0.27mmol) are dissolved in 10mL of isopropanol and 1g of basic Al are added2O3(9.80mmol) and then the reaction was refluxed at 75 ℃ for 5 h. TLC detection, complete reaction, suction filtration, concentration of filtrate to give crude product, silica gel column chromatography (DCM: MeOH) separation to give compound 3a 15 mg. 500mg of Compound 3a (2.62mmol) was dissolved in 10mL of DCM, 750. mu.L of phosphorus tribromide (7.90mmol) was added dropwise in an ice bath, reacted for 10min, and transferred to room temperature for reaction for 15 h. TLC monitoring, reaction completion, dichloromethane extraction 3 times, saturated salt water washing 1 time, anhydrous Na2SO4Dried, filtered and concentrated to give 652mg of a yellow solid. The resulting solid was dissolved in 10mL of DMF, and 10mL of aqueous ammonia was added to the solution to react at room temperature overnight. TLC monitoring, complete reaction, ethyl acetate extraction 3 times, saturated salt water washing 1 time, anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Separating with silica gel column chromatography (DCM: MeOH) to obtain compound 4a (R ═ CH)3)。
Example 1 the procedure for the synthesis of 7a in step (3) was replaced by: 26.4mg of compound 4a (0.14mmol) was dissolved in 4mL of anhydrous dichloromethane, and 39.9mg of EDCI (0.21mmol), 22.5mg of HOBt (0.17mmol), 46.5mg of compound 6a (0.14mmol) were added and reacted at room temperature for 6 h. After the reaction was completed, the reaction solution was poured into water, extracted with dichloromethane 3 times, washed with saturated brine 1 time, and anhydrous Na2SO4Drying and concentrating to obtain a crude product. Silica gel column chromatography (DCM: MeOH) afforded title compound 7 c.
The remaining steps were performed according to example 1 to obtain compound 7c as a white solid with a yield of 61.0%.1H NMR(CDCl3,400MHz),δ:8.18(1H,s,-CHO),7.99(1H,s,2-H),7.96(1H,d,J＝2.1Hz,5-H),7.51(1H,dd,J＝8.6,2.1Hz,7-H),7.38(1H,d,J＝6.8Hz,8-H),6.95(2H,d,J＝8.7Hz,Ar-H),6.73(1H,m,-NH),6.44(1H,m,-NH),6.42(2H,J＝8.7Hz,Ar-H),4.68(1H,m,-CH),4.24,4.17(each 1H,dd,J＝14.3,6.5Hz,-CH2),3.54(8H,m,-CH2),3.00,2.90(each 1H,dd,J＝14.0,5.5Hz,-CH2),2.47(3H,s,-CH3)；13C NMR(CDCl3,100MHz),δ:177.7,170.5,160.6,154.8,154.4,145.0,135.5,135.3,130.6(2),124.9,124.8,123.5,120.4,118.1,112.0(2),53.4(2),53.1,40.3(2),37.6,35.7,21.0；HRMS(ESI)m/z calcd for C25H26Cl2N3O4[M-H]-502.1300,found 502.1294。
Example 4
Example 1 the procedure for the synthesis of 3a in step (1) was replaced by: 553mg of Compound 1b (3.33mmol) were dissolved in 10mL of DMF, and then 630. mu.L of phosphorus oxychloride (6.72mmol) was added dropwise and reacted at room temperature for 12 hours. TLC monitoring, reaction is almost complete, 15mL water is added, crystal is separated out, suction filtration and drying are carried out, and the intermediate 2b 410mg is obtained. 55mg of intermediate 2b (0.27mmol) were dissolved in 10mL of isopropanol and 1g of basic Al was added2O3(9.80mmol) and then the reaction was refluxed at 75 ℃ for 5 h. TLC, reaction was complete, suction filtered and the filtrate was concentrated to give crude product which was separated using silica gel column chromatography (DCM: MeOH 300: 1) to give compound 3b 22 mg. 540mg of compound 3b (2.62mmol) was dissolved in 10mL of DCM, 750. mu.L of phosphorus tribromide (7.90mmol) was added dropwise in an ice bath, reacted for 10min, and transferred to room temperature for reaction for 15 h. TLC monitoring, reaction completion, dichloromethane extraction 3 times, saturated salt water washing 1 time, anhydrous Na2SO4Dried, filtered and concentrated to afford 681mg of a yellow solid. The resulting solid was dissolved in 10mL of DMF, and 10mL of aqueous ammonia was added to the solution to react at room temperature overnight. TLC monitoring, complete reaction, ethyl acetate extraction 3 times, saturated salt water washing 1 time, anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Separating with silica gel column chromatography (DCM: MeOH) to obtain compound 4b (R ═ OCH)3)。
Example 1 the procedure for the synthesis of 7a in step (3) was replaced by: 28.7mg of compound 4b (0.14mmol) were dissolved in 4mL of anhydrous dichloromethane, and 39.9mg of EDCI (0.21mmol), 22.5mg of HOBt (0.17mmol), 46.5mg of compound 6a (0.14mmol) were added and reacted at room temperature for 6 h. After the reaction was completed, the reaction solution was poured into water, extracted with dichloromethane 3 times, washed with saturated brine 1 time, and anhydrous Na2SO4Drying and concentrating to obtain a crude product. Silica gel column chromatography (DCM: MeOH) afforded title compound 7 d.
The remaining steps were performed according to the synthetic method of example 1 to obtain compound 7d as a white oil with a yield of 51.2%.1H NMR(CDCl3,600MHz),δ:8.18(1H,s,-CHO),7.99(1H,s,2-H),7.52(1H,d,J＝2.8Hz,5-H),7.43(1H,d,J＝9.0Hz,8-H),7.30(1H,dd,J＝9.0,2.8Hz,7-H),6.97(2H,d,J＝8.3Hz,Ar-H),6.64(1H,m,-NH),6.44(2H,d,J＝8.3Hz,Ar-H),6.30(1H,d,J＝6.1Hz,-NH),4.66(1H,m,-CH),4.23(2H,m,-CH2),3.90(3H,s,-OCH3),3.55(8H,m,-CH2),3.01,2.91(each 1H,m,-CH2)；13C NMR(CDCl3,150MHz),δ:117.5,170.5,160.6,157.1,154.1,151.4,145.0,130.6(2),124.7,124.4,124.1,119.8,119.7,112.0(2),104.7,56.0,53.4(2),53.1,40.3(2),37.5,35.7；HRMS(ESI)m/z calcd for C25H26Cl2N3O5[M-H]-518.1250,found 518.1246。
Example 5
Example 1 the procedure for the synthesis of 6a in step (2) was replaced by: 100.5mg of melphalan 5(0.33mmol) was dissolved in 10mL of dioxane, and then 0.9mL of di-tert-butyl carbonate (3.92mmol) and 0.59mL of triethylamine (4.26mmol) were added to the solution, followed by reaction at room temperature for 6 hours. After completion of the reaction, an appropriate amount of water was added, and extraction was performed 3 times with methylene chloride, washing with saturated brine was performed 1 time, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain Compound 6b (R)1＝-OC(CH3)3)。
The remaining steps were performed according to the synthetic method of example 1 to obtain compound 8a as colorless oil in 39.2% yield.1H NMR(CDCl3,400MHz),δ:8.03(1H,d,J＝1.8Hz,5-H),7.91(1H,s,2-H),7.51(1H,dd,J＝8.6,1.8Hz,7-H),7.38(1H,d,J＝8.6Hz,8-H),6.97(2H,d,J＝8.7Hz,Ar-H),6.47(2H,d,J＝8.7Hz,Ar-H),5.13,5.04(each 1H,d,J＝12,7Hz,-CH2),4.99(1H,d,J＝7.8Hz,-NH),4.54,(1H,m,-CH),3.62(4H,m,-CH2),3.55(4H,m,-CH2),3.02,2.95(each 1H,m,-CH2),2.46(3H,s,-CH3),1.41(9H,s,t-Bu-H)；13C NMR(CDCl3,100MHz),δ:176.51,172.09,155.80,155.13,154.70,144.99,135.63,135.31,130.69(2),125.24,124.77,123.66,118.84,117.95,111.99(2),79.93,58.96,54.63,53.46(2),40.33(2),37.14,28.31(3),20.97；HRMS(ESI)m/z calcd for C29H33Cl2N2O6[M-H]-575.1716,found 575.1713。
Example 6
Example 1 the procedure for the synthesis of 3a in step (1) was replaced by: 553mg of Compound 1b (3.33mmol) were dissolved in 10mL of DMF, and then 630. mu.L of phosphorus oxychloride (6.72mmol) was added dropwise and reacted at room temperature for 12 hours. TLC monitoring, reaction is almost complete, 15mL water is added, crystal is separated out, suction filtration and drying are carried out, and the intermediate 2b 410mg is obtained. 55mg of intermediate 2b (0.27mmol) were dissolved in 10mL of isopropanol and 1g of basic Al was added2O3(9.80mmol) and then the reaction was refluxed at 75 ℃ for 5 h. TLC monitoring, reaction completed, suction filtration, filtrate concentration to get crude product, silica gel column chromatography (DCM: MeOH) separation to get compound 3b (R ═ OCH)3)。
Example 1 the procedure for the synthesis of 6a in step (2) was replaced by: 100.5mg of melphalan 5(0.33mmol) was dissolved in 10mL of dioxane, and then 0.9mL of di-tert-butyl carbonate (3.92mmol) and 0.59mL of triethylamine (4.26mmol) were added to the solution, followed by reaction at room temperature for 6 hours. After completion of the reaction, an appropriate amount of water was added, and extraction was performed 3 times with methylene chloride, washing with saturated brine was performed 1 time, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain Compound 6b (R)1＝-OC(CH3)3)。
The remaining steps were performed according to example 1 to obtain compound 8b as a colorless oil in 35.9% yield.1H NMR(CDCl3,400MHz),δ:7.91(1H,s,2-H),7.59(1H,d,J＝3.1Hz,5-H),7.41(1H,d,J＝9.2Hz,8-H),7.28(1H,dd,J＝9.2,3.1Hz,7-H),6.97(2H,d,J＝8.7Hz,Ar-H),6.49(2H,d,J＝8.7Hz,Ar-H),5.14,5.05(each 1H,d,J＝12.6Hz,-CH2),5.00(1H,d,J＝8.2Hz,-NH),4.54(1H,m,-CH),3.89(3H,s,-OCH3),3.63(4H,m,-CH2),3.55(4H,m,-CH2),3.01,2.96(each 1H,m,-CH2),1.41(9H,s,t-Bu-H)；13C NMR(CDCl3,100MHz),δ:176.26,172.09,157.21,155.58,155.14,151.25,144.97,130.68(2),124.84,124.59,124.10,119.62,118.23,112.04(2),104.99,79.92,58.99,55.97,54.64,53.48(2),40.33(2),37.14,28.31(3)；HRMS(ESI)m/z calcd for C29H33Cl2N2O7[M-H]-591.1665,found 591.1677。
Example 7
Example 1 the procedure for the synthesis of 3a in step (1) was replaced by: 500mg of compound 1a (3.33mmol) was dissolved in 10mL of DMF, and 630. mu.L of phosphorus oxychloride (6.72mmol) was added dropwise and reacted at room temperature for 12 hours. TLC monitoring, reaction is almost complete, 15mL water is added, crystal is separated out, suction filtration and drying are carried out, and the intermediate 2a 402.4mg is obtained. 50mg of intermediate 2a (0.27mmol) are dissolved in 10mL of isopropanol and 1g of basic Al are added2O3(9.80mmol) and then the reaction was refluxed at 75 ℃ for 5 h. TLC detection, complete reaction, suction filtration, concentration of filtrate to give crude product, silica gel column chromatography (DCM: MeOH) separation to give compound 3a 15 mg. 500mg of Compound 3a (2.62mmol) was dissolved in 10mL of DCM, 750. mu.L of phosphorus tribromide (7.90mmol) was added dropwise in an ice bath, reacted for 10min, and transferred to room temperature for reaction for 15 h. TLC monitoring, reaction completion, dichloromethane extraction 3 times, saturated salt water washing 1 time, anhydrous Na2SO4Dried, filtered and concentrated to give 652mg of a yellow solid. The resulting solid was dissolved in 10mL of DMF, and 10mL of aqueous ammonia was added to the solution to react at room temperature overnight. TLC monitoring, complete reaction, ethyl acetate extraction 3 times, saturated salt water washing 1 time, anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Separating by silica gel column chromatography (DCM: MeOH) to obtain compound 4a (R ═-CH3)。
Example 1 the procedure for the synthesis of 6a in step (2) was replaced by: 100.5mg of melphalan 5(0.33mmol) was dissolved in 10mL of dioxane, and then 0.9mL of di-tert-butyl carbonate (3.92mmol) and 0.59mL of triethylamine (4.26mmol) were added to the solution, followed by reaction at room temperature for 6 hours. After completion of the reaction, an appropriate amount of water was added, and extraction was performed 3 times with methylene chloride, washing with saturated brine was performed 1 time, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain Compound 6b (R)1＝-OC(CH3)3)。
Example 1 the procedure for the synthesis of 7a in step (3) was replaced by: 26.4mg of compound 4a (0.14mmol) was dissolved in 4mL of anhydrous dichloromethane, and 39.9mg of EDCI (0.21mmol), 22.5mg of HOBt (0.17mmol), 56.6mg of compound 6b (0.14mmol) were added and reacted at room temperature for 6 h. After the reaction was completed, the reaction solution was poured into water, extracted with dichloromethane 3 times, washed with saturated brine 1 time, and anhydrous Na2SO4Drying and concentrating to obtain a crude product. Silica gel column chromatography (DCM: MeOH) afforded title compound 8 c.
The remaining steps were performed according to example 1 to obtain compound 8c as a white oil in 49.4% yield.1H NMR(CDCl3,400MHz),δ:8.00(1H,s,2-H),7.95(1H,d,J＝2.1Hz,5-H),7.50(1H,dd,J＝8.6,2.1Hz,7-H),7.37(1H,d,J＝8.6Hz,8-H),6.96(2H,d,J＝8.6Hz,Ar-H),6.64(1H,m,-NH),6.43(2H,J＝8.6Hz,Ar-H),5.00(1H,s,-NH),4.2(3H,m,-CH2,-CH),3.55(8H,m,-CH2),2.97,2.88(each 1H,m,-CH2),2.46(3H,s,-CH3),1.39(9H,s,t-Bu-H)；13C NMR(CDCl3,100MHz),δ:177.7,171.5,154.8,154.3,144.9,135.3,135.2,130.6(2),125.2,124.9,123.6,120.6,118.0,112.0(2),80.1,55.8,53.4(2),40.3(2),37.6,35.4,29.7,28.3(3),21.0；HRMS(ESI)m/z calcd for C29H34Cl2N3O5[M-H]-574.1876,found 574.1889。
Example 8
Example 1 Synthesis in step (1)The steps of 3a are replaced by: 553mg of Compound 1b (3.33mmol) were dissolved in 10mL of DMF, and then 630. mu.L of phosphorus oxychloride (6.72mmol) was added dropwise and reacted at room temperature for 12 hours. TLC monitoring, reaction is almost complete, 15mL water is added, crystal is separated out, suction filtration and drying are carried out, and the intermediate 2b 410mg is obtained. 55mg of intermediate 2b (0.27mmol) were dissolved in 10mL of isopropanol and 1g of basic Al was added2O3(9.80mmol) and then the reaction was refluxed at 75 ℃ for 5 h. TLC detection, complete reaction, suction filtration, concentration of filtrate to give crude product, silica gel column chromatography (DCM: MeOH) separation to give compound 3b 22 mg. 540mg of compound 3b (2.62mmol) was dissolved in 10mL of DCM, 750. mu.L of phosphorus tribromide (7.90mmol) was added dropwise in an ice bath, reacted for 10min, and transferred to room temperature for reaction for 15 h. TLC monitoring, reaction completion, dichloromethane extraction 3 times, saturated salt water washing 1 time, anhydrous Na2SO4Dried, filtered and concentrated to afford 681mg of a yellow solid. The resulting solid was dissolved in 10mL of DMF, and 10mL of aqueous ammonia was added to the solution to react at room temperature overnight. TLC monitoring, complete reaction, ethyl acetate extraction 3 times, saturated salt water washing 1 time, anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Separating with silica gel column chromatography (DCM: MeOH) to obtain compound 4b (R ═ OCH)3)。
Example 1 the procedure for the synthesis of 6a in step (2) was replaced by: 100.5mg of melphalan 5(0.33mmol) was dissolved in 10mL of dioxane, and then 0.9mL of di-tert-butyl carbonate (3.92mmol) and 0.59mL of triethylamine (4.26mmol) were added to the solution, followed by reaction at room temperature for 6 hours. After completion of the reaction, an appropriate amount of water was added, and extraction was performed 3 times with methylene chloride, washing with saturated brine was performed 1 time, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain Compound 6b (R)1＝-OC(CH3)3)。
Example 1 the procedure for the synthesis of 7a in step (3) was replaced by: 28.7mg of compound 4b (0.14mmol) were dissolved in 4mL of anhydrous dichloromethane, and 39.9mg of EDCI (0.21mmol), 22.5mg of HOBt (0.17mmol), 56.6mg of compound 6b (0.14mmol) were added and reacted at room temperature for 6 h. After the reaction was completed, the reaction solution was poured into water, extracted with dichloromethane 3 times, washed with saturated brine 1 time, and anhydrous Na2SO4Drying and concentrating to obtain a crude product. Silica gel column chromatography (DCM: MeOH) afforded title compound 8 d.
The remaining steps were performed according to example 1 to obtain compound 8d as a colorless oil in 34.6% yield.1H NMR(CDCl3,400MHz),δ:8.00(1H,s,2-H),7.52(1H,d,J＝3.0Hz,5-H),7.42(1H,d,J＝9.2Hz,8-H),7.28(1H,dd,J＝9.2,3.0Hz,7-H),6.98(2H,d,J＝8.7Hz,Ar-H),6.63(1H,m,-NH),6.46(2H,d,J＝8.7Hz),4.97(1H,s,-NH),4.23(2H,m,-CH2),3.89(3H,s,-OCH3),3.56(8H,m,-CH2),2.96,2.89(each 1H,m,-CH2),1.39(9H,s,t-Bu-H)；13C NMR(CDCl3,100MHz),δ:177.5,171.5,157.0,154.1(2),151.4,144.9,130.6(2),125.2,124.5,124.0,120.1,119.7,112.1(2),104.7,55.9(2),53.4(2),40.3(2),37.5,35.4,29.7,28.3(3)；HRMS(ESI)m/z calcd for C29H34Cl2N3O6[M-H]-590.1825,found 590.1823。
Example 9
The following are the results of pharmacological experiments with some of the compounds of the invention:
experimental equipment and reagent
Instrument clean bench (Sujing group Antai company)
Constant temperature incubator (Thermo electronic Corporation)
Enzyme-linked immunosorbent assay (BIO-RAD company)
Inverted biological microscope (Chongqing optical instrument factory)
Reagent cell culture Medium RPMI-1640, DMEM (high sugar) (GIBCO Co., Ltd.)
Fetal bovine serum (Hangzhou Sijiqing Co., Ltd.)
CCK-8(Biosharp company product)
DMSO (Sigma Co.)
Cell lines of human breast cancer cells MCF-7, human breast cancer cells MDA-MB-231,
Human liver cancer cells HepG2, Bel-7402
Experimental methods
Cell inhibitory activity test method
Cells were incubated at 37 ℃ with 5% CO2Culturing in an incubator with saturated humidity. The culture medium is high containing 10% heat-inactivated fetal calf serum, penicillin 100U/mL and streptomycin 100U/mLGlycodmem cell culture medium. The culture medium was changed for 48h, and after the cells were attached to the wall, they were digested with 0.25% trypsin for passage. The cells for experiment are all in logarithmic growth phase, and the CCK-8 method shows the cell activity>95％。
Taking a bottle of cells in a logarithmic phase, adding a digestive juice (0.125% trypsin and 0.01% EDTA) for digestion, and counting by 2-4 × 104cell/mL, preparing cell suspension, inoculating on 96-well plate, 100 μ L/well, and placing in constant temperature CO2The culture was carried out in an incubator for 24 hours. The solution was changed, the test drug was added at 100. mu.L/well, and cultured for 72 hours. CCK-8 was added to 96-well plates at 50. mu.L/well and incubated in an incubator for 4 hours. The supernatant was aspirated, DMSO was added at 200. mu.L/well and shaken on a shaker for 10 min. The test substances were examined at 6 concentrations of 0.001 to 100. mu.M in ten-fold increments, and the cell inhibition rate at each concentration was calculated by measuring the absorbance of each well at a wavelength of 450nm using an enzyme-linked immunosorbent assay.
The inhibition rate calculation method comprises the following steps:
relative OD value of drug sensitive well (absolute OD value of drug sensitive well) — absolute OD value of blank control well
Results of the experiment
TABLE 1 examples IC for antiproliferative activity against 2 human breast cancer and 1 human hepatoma cell lines50Value (μ M)
Pharmacological tests prove that the target derivative has better anti-breast cancer and anti-liver cancer cell proliferation activity, and can be used for further preparing anti-tumor drugs.
Claims (8)
1. A nitrogen mustard chromone derivative shown in a general formula I and pharmaceutically acceptable salts thereof:
wherein R is an alkyl or alkoxy group containing 1 to 8 carbon atoms; r1Is H, or an alkyl or alkoxy group containing 1 to 10 carbon atoms; the heteroatom X is N, O, S or Se.
2. The nitrogen mustard chromone derivative of formula I and the pharmaceutically acceptable salts thereof of claim 1 wherein:
in the general formula I, R is alkyl or alkoxy containing 1-6 carbon atoms; r1Is H, or an alkyl or alkoxy group containing 1 to 8 carbon atoms; the heteroatom X is N, O or S.
3. The nitrogen mustard chromone derivative of formula I and the pharmaceutically acceptable salts thereof of claim 1 wherein:
in the general formula I, R is alkyl or alkoxy containing 1-4 carbon atoms; r1Is H, or an alkyl or alkoxy group containing 1 to 6 carbon atoms; the heteroatom X is N or O.
4. The nitrogen mustard chromone derivative of formula I and pharmaceutically acceptable salts thereof according to any one of claims 1-3 wherein: the structural formula of the nitrogen mustard chromone derivative and the pharmaceutically acceptable salt thereof is shown as a-h:
5. a pharmaceutical composition characterized by: the pharmaceutical composition contains a therapeutically effective amount of the nitrogen mustard chromone derivative shown in the general formula I and the pharmaceutically acceptable salt thereof, which are shown in any one of claims 1 to 4, and a pharmaceutically acceptable carrier.
6. Use of the nitrogen mustard chromone derivative shown in the general formula I and the pharmaceutically acceptable salt thereof in any one of claims 1 to 4 in the preparation of medicaments for treating tumor diseases.
7. Use of the pharmaceutical composition of claim 5 for the preparation of a medicament for the treatment of a neoplastic disease.
8. Use according to claim 6 or 7, characterized in that: the tumor is breast cancer tumor or liver cancer tumor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111227792.2A CN113717138B (en) | 2021-10-21 | 2021-10-21 | Nitrogen mustard chromone derivatives and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111227792.2A CN113717138B (en) | 2021-10-21 | 2021-10-21 | Nitrogen mustard chromone derivatives and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113717138A true CN113717138A (en) | 2021-11-30 |
| CN113717138B CN113717138B (en) | 2023-02-24 |
Family
ID=78686117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111227792.2A Active CN113717138B (en) | 2021-10-21 | 2021-10-21 | Nitrogen mustard chromone derivatives and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113717138B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115260140A (en) * | 2022-08-31 | 2022-11-01 | 贵州医科大学 | Chromone-phenoxymethyl alpha-glucosidase inhibitor and preparation method and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120264731A1 (en) * | 2011-04-13 | 2012-10-18 | Astrazeneca Ab | Chromenone derivatives |
| US20150011618A1 (en) * | 2012-01-13 | 2015-01-08 | Beijing Shenogen Pharma Group Ltd. | Synthesis of polyhydroxy chromenone compounds and their anti-tumor effects |
| CN107674076A (en) * | 2017-09-20 | 2018-02-09 | 沈阳药科大学 | One kind has the preparation method and purposes of the rutaecarpin split nitrogen mustard derivatives of antitumor activity |
| CN108276424A (en) * | 2018-01-18 | 2018-07-13 | 沈阳药科大学 | A kind of plectranthin type kauran diterpene split nitrogen mustard derivatives and its preparation method and application |
| CN108864024A (en) * | 2018-08-10 | 2018-11-23 | 沈阳药科大学 | A kind of Scutellarein mustargen analog derivative and its preparation method and application |
| CN109134487A (en) * | 2018-08-10 | 2019-01-04 | 沈阳药科大学 | Compound and its preparation method and application of the one kind containing benzoic acid nitrogen mustard segment |
| CN113416189A (en) * | 2021-07-14 | 2021-09-21 | 沈阳药科大学 | Beta-cabbagine mustard derivative, preparation method and anti-tumor application |
-
2021
- 2021-10-21 CN CN202111227792.2A patent/CN113717138B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120264731A1 (en) * | 2011-04-13 | 2012-10-18 | Astrazeneca Ab | Chromenone derivatives |
| US20150011618A1 (en) * | 2012-01-13 | 2015-01-08 | Beijing Shenogen Pharma Group Ltd. | Synthesis of polyhydroxy chromenone compounds and their anti-tumor effects |
| CN107674076A (en) * | 2017-09-20 | 2018-02-09 | 沈阳药科大学 | One kind has the preparation method and purposes of the rutaecarpin split nitrogen mustard derivatives of antitumor activity |
| CN108276424A (en) * | 2018-01-18 | 2018-07-13 | 沈阳药科大学 | A kind of plectranthin type kauran diterpene split nitrogen mustard derivatives and its preparation method and application |
| CN108864024A (en) * | 2018-08-10 | 2018-11-23 | 沈阳药科大学 | A kind of Scutellarein mustargen analog derivative and its preparation method and application |
| CN109134487A (en) * | 2018-08-10 | 2019-01-04 | 沈阳药科大学 | Compound and its preparation method and application of the one kind containing benzoic acid nitrogen mustard segment |
| CN113416189A (en) * | 2021-07-14 | 2021-09-21 | 沈阳药科大学 | Beta-cabbagine mustard derivative, preparation method and anti-tumor application |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115260140A (en) * | 2022-08-31 | 2022-11-01 | 贵州医科大学 | Chromone-phenoxymethyl alpha-glucosidase inhibitor and preparation method and application thereof |
| CN115260140B (en) * | 2022-08-31 | 2024-01-19 | 贵州医科大学 | Chromone-phenoxymethyl alpha-glucosidase inhibitor and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113717138B (en) | 2023-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108864024B (en) | Scutellarin aglycone nitrogen mustard derivative and preparation method and application thereof | |
| CN111196801B (en) | Aporphine alkaloid derivative and preparation method and application thereof | |
| CN111072682A (en) | Chelidonine furazan nitric oxide donor derivative and preparation method and application thereof | |
| CN113717138B (en) | Nitrogen mustard chromone derivatives and application thereof | |
| CN113416189B (en) | Beta-carbopol Lin Dangai derivative, preparation method and anti-tumor application | |
| CN110981882B (en) | Chelidonium nitric oxide donor derivatives, and preparation method and application thereof | |
| CN110981881B (en) | Chelidonine nitric oxide donor derivative and preparation method and application thereof | |
| CN106928293A (en) | One class has furazan NO donator type scutellarin derivatives of antitumor activity and its production and use | |
| CN108276424B (en) | Plectranthin type kaurane diterpene assembled nitrogen mustard derivative and preparation method and application thereof | |
| CN110028477B (en) | Preparation method and application of 4-site split nitrogen mustard derivatives of brefeldin A | |
| CN113788809B (en) | 3-site mosaic nitrogen mustard derivative of chromone and application | |
| CN111892537B (en) | Aporphine alkaloid derivative and preparation method and application thereof | |
| CN110964033B (en) | Oridonin 14-position hydrogen sulfide donor derivative and preparation method and application thereof | |
| CN113788810B (en) | Chromone nitrogen mustard derivative and anti-tumor application | |
| CN106883277A (en) | One class has furazan class NO donator type scutellarin derivatives of antitumor activity and its production and use | |
| CN109400595B (en) | Anticancer compound containing thiophene ring | |
| CN113563330B (en) | 3-position derivative of beta-carbopol as well as preparation method and application thereof | |
| CN110981886A (en) | Hydrogen sulfide donor derivative of diterpene dimer and preparation method and application thereof | |
| CN107382944B (en) | Coumarin gossypol derivatives with anti-tumor activity and synthesis method thereof | |
| CN109810119B (en) | Isodon japonicus type diterpene derivative and preparation method and application thereof | |
| CN110950883A (en) | 1-site oxidation oridonin hydrogen sulfide donor derivative and application thereof | |
| CN113563331B (en) | Nitrogen mustard beta-carbopol derivative and preparation method and application thereof | |
| CN112745310B (en) | Chromone 2-piperazine linked furazan derivative and preparation method and application thereof | |
| CN111635396B (en) | Spirolactone type diterpene split hydrogen sulfide donor derivative and preparation method and application thereof | |
| CN113651867B (en) | Sulfonamide 18 beta-glycyrrhetinic acid derivative and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |